Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Vyome Holdings, Inc. Common Stock

HIND

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.48 – $1.59
Volume 5,646
Market cap $11M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.74M
Price / earnings
—
Price / book
2.02×
Price / sales
70.14×
EV / sales
24.7×
EV / EBITDA
-0.87×

Profitability

Earnings per share
-$0.58
Return on assets
-47.18%
Return on equity
-76.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.68×
Quick ratio
3.68×
Cash ratio
3.37×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.45M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HIND, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$58K$26.96K$31.59K$36.55K$34.63K
Cost of revenue$31.2K$15.3K$14.95K$14.49K$16.58K
Gross profit$26.8K$11.66K$16.65K$22.07K$18.05K
Selling, general and administrative$635.41K$364.89K$477.58K$996.2K$844.34K
Research and development$409.83K$506.72K$666.41K$378.25K$39.68K
Total operating expenses$1.05M$874.22K$1.15M$1.38M$8.59M
Operating income-$1.02M-$862.57K-$1.13M-$1.36M-$8.57M
Interest expense-$2.94K-$3.33K-$2.85K-$9.94K-$25.6K
Income before taxes-$930.33K-$719.68K-$985.52K-$1.28M-$8.6M
Income taxes$0$0$0$0$0
Net income-$930.33K-$719.68K-$985.52K-$1.28M-$8.6M
Net income attributable to common shareholders-$885.41K-$685.56K-$1.02M-$1.47M-$8.43M
EBITDA-$1.02M-$859.96K-$1.13M-$1.35M-$8.57M
Basic earnings per share-$0.13-$0.10-$0.15-$0.25-$3.06
Diluted earnings per share-$0.13-$0.10-$0.15-$0.25-$3.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 15, 20251-for-4reverse split